Stockscreener 앱 받기
186.42
4.68%
8.34
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Published on: 2025-11-15 06:25:23 - newser.com
How analysts rate Praxis Precision Medicines Inc. stock todayPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
How institutional buying supports Praxis Precision Medicines Inc. stockJuly 2025 Momentum & Free Fast Entry Momentum Trade Alerts - newser.com
Using fundamentals and technicals on Praxis Precision Medicines Inc.2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Is Praxis Precision Medicines Inc. stock a contrarian buy2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesMarket Growth Summary & Weekly Setup with High ROI Potential - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockWeekly Risk Summary & Smart Allocation Stock Reports - newser.com
PRAX: HC Wainwright & Co. Raises Price Target to $258 | PRAX Sto - GuruFocus
Published on: 2025-11-12 17:26:58 - newser.com
Published on: 2025-11-12 08:52:54 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsWeekly Earnings Recap & Community Verified Trade Signals - newser.com
(PRAX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Published on: 2025-11-10 01:11:09 - newser.com
Published on: 2025-11-09 22:42:30 - newser.com
Praxis Precision Medicines Reports Q3 2025 Financial Results - MSN
Published on: 2025-11-08 04:02:56 - newser.com
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $270 From $280, Maintains Buy Rating - MarketScreener
Praxis Precision Medicines (PRAX) Is Up After Positive Ulixacaltamide Trial and FDA Alignment on RelutrigineHas the Investment Thesis Gained New Momentum? - Sahm
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline - Investing.com Canada
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline By Investing.com - Investing.com South Africa
Wedbush Raises Price Target on Praxis Precision Medicines to $77 From $73, Keeps Underperform Rating - MarketScreener
PRAX: Wedbush Raises Price Target While Maintaining Underperform Rating | PRAX Stock News - GuruFocus
Praxis Precision announces inducement grants under Nasdaq lsiting rule - TipRanks
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) grants 6,876 RSUs under 2024 Inducement Plan - Stock Titan
Is a relief rally coming for Praxis Precision Medicines Inc. holders2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - Markets Financial Content
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beat2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
1.43%
0.07%
자본화:
|
볼륨(24시간):